Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Squalamine eye drops in neovascular AMD
NCT01678963Phase 2Completed
- Sponsor
- Ohr Pharmaceutical, Inc.
- Start
- Nov 2012
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
A Phase 2 trial of squalamine in neovascular age-related macular degeneration (NVAMD), sponsored by Ohr Pharmaceutical, Inc.. Started Nov 2012; status: completed.
02
Drugs
squalamine
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01678963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678963.